Publications by authors named "Minori Baba"
Transl Oncol
November 2022
Article Synopsis
- - T-cell receptor-engineered therapies show promise for treating synovial sarcoma, but their effectiveness is limited by the need for human leukocyte antigen (HLA) matching, which chimeric antigen receptor (CAR) therapies can potentially bypass by targeting tumor-associated antigens directly.
- - Researchers analyzed synovial sarcoma cell lines and found that ligands for NK cell-activating receptors like NKp44 and NKp30 were expressed, while others like NKp46 had no expression, suggesting potential for targeted therapy.
- - The study indicated that NKp44-based CAR T cells could specifically recognize and suppress synovial sarcoma cell growth, making CAR therapies a viable option for this type of cancer treatment.
